BOS Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about BOS clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 34 trials

Recruiting
Phase 3

REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

Cancer-Associated Thrombosis (CAT)
Regeneron Pharmaceuticals860 enrolled5 locationsNCT07410117
Recruiting

Indicators Affecting PVT Recanalization

CirrhosisPortal Hypertension Related to CirrhosisPortal Vein Thrombosis+1 more
Shanghai Zhongshan Hospital1,500 enrolled1 locationNCT07473375
Recruiting
Phase 1

Positron Emission Tomography (PET) Imaging of Thrombosis

CancerAtrial FibrillationThrombosis+1 more
Massachusetts General Hospital165 enrolled1 locationNCT03830320
Recruiting

Study of Risk Factors and Prediction of Blood Clots After Lung Cancer Surgery

Lung Cancer (Diagnosis)Venous Thromboembolism (VTE)Deep Vein Thrombosis (DVT)
The First Hospital of Jilin University900 enrolled1 locationNCT07439991
Recruiting
Not Applicable

Thrombin Generation Parameters and Bleeding in Patients Treated With Anticoagulants for Cancer Associated Thrombosis

CancerThrombosisPulmonary Embolism
Centre Hospitalier Universitaire de Saint Etienne212 enrolled4 locationsNCT06386107
Recruiting
Phase 2

QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT

BevacizumabHepatecellular CarcinomaRALOX-HAIC(Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin+3 more
Nanfang Hospital, Southern Medical University38 enrolled1 locationNCT07327788
Recruiting
Phase 3

Thromboprophylaxis in Lower Limb Immobilisation

ThrombosisInjury Leg
Queen Mary University of London10,044 enrolled3 locationsNCT06370273
Recruiting

Generative AI Impact on Rheumatoid Arthritis Complications Diagnosis

Cardiovascular DiseasesOsteoporosisThrombosis+12 more
Guang'anmen Hospital of China Academy of Chinese Medical Sciences100 enrolled1 locationNCT07301892
Recruiting
Not Applicable

Intracardiac Echocardiography Guided Watchman Device Implant

Atrial FibrillationLeft Atrial Appendage Thrombosis
The Cleveland Clinic100 enrolled1 locationNCT06007872
Recruiting
Phase 4

Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC

CirrhosisHCC - Hepatocellular CarcinomaPortal Vein Thrombosis
Mansoura University100 enrolled1 locationNCT07132515
Recruiting
Not Applicable

Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery

SurgeryCancerVenous Thromboembolism+2 more
Medical University of South Carolina30 enrolled1 locationNCT06451003
Recruiting
Phase 2

Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT

Thrombosis, Deep VeinIliofemoral; Thrombosis
Mercator MedSystems, Inc.80 enrolled17 locationsNCT04862468
Recruiting

Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform

Myelodysplastic SyndromesShwachman-Diamond SyndromeSDS+24 more
Shwachman-Diamond Syndrome Alliance Inc8,000 enrolled1 locationNCT06999954
Recruiting
Not Applicable

The Impact of MTM Model on the Efficacy and Safety of Anticoagulant Therapy in Postoperative Colorectal Cancer Patients

Thrombosis, Venous
Sixth Affiliated Hospital, Sun Yat-sen University327 enrolled1 locationNCT06998745
Recruiting

Immune Checkpoint Inhibitor Associated Cardiovascular Adverse Events in Patients With Cancer

CancerCardiovascular DiseasesStroke+4 more
Hanneke W. M. van Laarhoven214 enrolled1 locationNCT06519292
Recruiting
Phase 2

Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma

Sarcoma,Soft TissueBrachytherapyPoly(ADP-ribose) Polymerase Inhibitors
Fujun Zhang32 enrolled1 locationNCT05894018
Recruiting

PIVKA-II for Predicting Portal Vein Thrombosis in Hepatocellular Carcinoma

Hepato Cellular Carcinoma (HCC)Portal Vein Tumour Thrombosis
Tanta University116 enrolled1 locationNCT06960954
Recruiting

Stroke Risk Assessment and Markers of Blood Clotting in Patients With Newly Diagnosed Non-valvular Atrial Fibrillation (NVAF), Who Have Not Received Oral Anticoagulation Therapy (OAC-therapy) Prior to Inclusion

ThrombosisStrokeAtrial Fibrillation (AF)+4 more
Nedim Tojaga150 enrolled1 locationNCT06949319
Recruiting
Phase 2

Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus

Renal Cell CarcinomaKidney CancerRenal Cancer+1 more
University of Colorado, Denver17 enrolled3 locationsNCT05969496
Recruiting
Early Phase 1

Apixaban in Thrombocytopenia

ThrombocytopeniaDeep Vein ThrombosisPulmonary Embolism and Thrombosis+1 more
Rushad Patell30 enrolled1 locationNCT06886516